Skip to content

Lifecore Biomedical, Inc. LFCR Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

ADMA Biologics logo
ADMA BiologicsADMA
$8M
Charles River Laboratories logo
Charles River LaboratoriesCRL
-$117.98M-3,595%

Segments

By segment

See full
Reportable Segment$0

Other financials

Income statement

See full
Revenue$23.2M-36.4%
Gross profit$4.5M-68.1%
Operating income-$4.7M
Net income-$15.0M-1,206%
EPS (diluted)-$0.43-1,333%

Balance sheet

See full
Cash & equivalents$20.8M+152%
Total debt$156.9M+1,310%
Total equity-$28.4M-2,229%
Total assets$225.5M-5.8%

Cash flow

See full
Operating cash flow$4.7M
CapEx$1.1M-46.7%
Free cash flow$3.6M

Valuation

See full
Market cap$196.92M-35.4%
Enterprise value$333.06M+8.3%
P/S1.6×+0.5×

Profitability

See full
Gross margin31.3%-1.4pp
Operating margin-14.5%-2.2pp
Net margin-30%
FCF margin-36.4%

Returns & leverage

See full
Return on equity-612.1%
Debt / equity8.3×-1.5×
Current ratio3.8×+0.9×

Where this comes from

Reported directly by Lifecore Biomedical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnSaleOfOtherAssets.

The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lifecore Biomedical, Inc.'s gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lifecore Biomedical, Inc.'s gain/loss on asset sales?
Lifecore Biomedical, Inc. (LFCR) reported gain/loss on asset sales of $0 in Q1 2026.
How has Lifecore Biomedical, Inc.'s gain/loss on asset sales changed year-over-year?
Lifecore Biomedical, Inc.'s gain/loss on asset sales increased by 100.0% year-over-year, from -$91K to $0.
What does gain/loss on asset sales mean?
Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.